SYNOPSIS Nine partial thromboplastin (cephalin) reagents have been compared in a parallel investigation of groups of patients on 'long-term' anticoagulants, a group with moderate haemophilia, and patients on heparin infusion.
The partial thromboplastin (cephalin) time is employed as an overall measure of 'intrinsic' blood clotting. Its main applications are in the screening for hereditary and acquired 'intrinsic' clotting defects and in assessing the intrinsic defect during oral anticoagulant treatment. The test involves the recalcification of platelet-poor plasma in the presence of a crude phospholipid extract. The origins of the latter vary and different animal tissues are used in their preparation. In addition 'home-made' phospholipid extracts from human brain may be made (Hjort, Rapaport, and Owren, 1955 ) and used at individual hospitals.
The present report describes the results encountered in clinical practice when a variety of reagents currently available in Britain are used. An attempt has been made to correlate these reagents with a 'standardized cephalin preparation'. The comparison of the cephalin reagents has been on patients on 'long-term' anticoagulants (nicoumalone therapy), a group with moderately severe haemophilia, and patients on heparin therapy.
On the basis of the findings a system for standardizing the cephalin time test has been introduced and involving the supply of a sensitive standardized cephalin preparation.
Diascreen, Hoechst and Hyland, and two of our own extracts of human brain (Hjort et al, 1955 With the human cephalin preparations A and B a kaolin-activated partial thromboplastin time was used, modified by Thomson (1970) , from the method of Egeberg (1961), using a 10-minute activation period.
A ratio method was used for the expression of results, namely, patient's cephalin time (sec) mean normal control cephalin time (sec) This seemed more valid for assessing the comparative sensitivity of the different reagents than simply recording the results of the individual cephalin times. The same principle is used with the British Comparative Thromboplastin when calibrating Quick prothrombin test reagents by correlation of results on anticoagulated patients (Poller, 1970) . The reliability of the ratio system depends on accurate normal values. Twenty fresh normal specimens, taken from healthy adults were therefore tested individually with each reagent to give a good normal mean. The ratios obtained in the coumarintreated group with each cephalin reagent were plotted against the 'standardized preparation' (human cephalin B). Results were plotted on arithmetic graph paper with the 'standardized' preparation (human B) on the ordinate, as in the prothrombin time thromboplastin correlation.
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The first group under study were stabilized 'longterm' patients on oral anticoagulant treatment. These normally show a prolongation of the cephalin time test which reflects depression of factors IX and X. The reliability and sensitivity of the available cephalin reagents were thus compared with the 'standardized preparation'. In the first part of the study, cephalin times were performed with each partial thromboplastin time reagent ,in duplicate on 26 specimens from patients treated on a 'long-term' basis with nicoumalone, Sinthrome. These patients were adequately anticoagulated having prothrombin ratios greater than 2-0 with the British Comparative Thromboplastin.
The commercial reagent Thrombofax Activated only became available towards the end of the study and had to be compared individually with the 'standardized preparation' (human cephalin B) on the 17 coumarin plasmas.
In order to characterize the sensitivity of the reagents to moderate to severe factor VIII deficiency, seven plasmas from haemophilic patients whose factor VIII lay between 1 and 10 % of pooled normal were tested individually with each commercial cephalin reagent and the 'standardized preparation'.
The results in this series were also expressed as a cephalin ratio.
A study was also initiated on patients on heparin treatment to assess the sensitivity to the presence of circulating anticoagulant and suitability of the commercial reagents and 'standardized preparation'. The patients were on continuous heparin administration by continuous drip and their plasma recalcification times were approximately twice the upper limit of normality.
Results

ORAL ANTICOAGULANT TREATMENT
The results with the nine partial thromboplastin reagents included in the trial are given in Table I . The figures represent the mean ratio of the 26 coumarin plasmas with the eight cephalin reagents in Table I. Table I also gives the mean cephalin time (sec) of the 20 normal control plasmas tested with each reagent. The least sensitive reagents gave ratios of 1 1 whereas the two most sensitive reagents gave mean ratios of 1-4 on the same group of coumarin plasmas. There was no correlation between the length of the mean normal control time and the sensitivity, ie, no increase in sensitivity to compensate for the increasing tedium of the test arising from the longer clotting times. The results for Thrombofax Activated are given in parallel with the 'standardized reagent'. Individual patient's blood Alderson, Poller, and Thomson (1970) (Hemker, Veltkamp, and Loeliger, 1968 Eastham (1968) has recommended the cephalin time as being more valuable than the Quick test in the regulation of long-term anticoagulant administration.
The value of the cephalin time in the diagnosis of haemophilia has been a matter for dispute. Sawers and Hirsh (1970) state:'The activated partial thromboplastin time test typically gives a prolonged clotting time in all grades of haemophilia except when the patient has recently received transfusion with fresh blood, or with poorly collected blood samples'. Most workers would accept the view that the partial thromboplastin time would probably give an abnormal result if the factor VIII was below 20% (Ingram, 1969) .
In the present investigations the variable sensitivity of the commercial reagents to moderate haemophilia is seen and indicates the great variation in sensitivity of these preparations to low factor VIII levels. The mean cephalin ratios for the seven haemophilics varied from 2-1 to 5-1 (see Table III ).
The prolongation of some of the tests was due to the indeterminate nature of the endpoint and not only to sensitivity to factor VIII levels. Only three reagents gave good endpoints, these were: the standardized material (human B), Diagen, and Diascreen, although the two commercial ones were relatively insensitive.
The cephalin time is also used for the clinical regulation of heparin dosage at some centres. The relative value of the different reagents in assessing the response is governed by two processes-the sensitivity to the anticoagulant effect of heparin and the quality of the endpoint. The results varied considerably (Table IV) . Only the human standardized preparation, and possibly Diagen and Diascreen could be recommended for heparin control as the endpoint was too poorly defined with the others.
Part II The preparation of a 'standardized cephalin' extract No system of quality control has hitherto been recommended for cephalin reagents and there has been little appreciation of the effect of variation of reagents on the sensitivity of the tests.
The first step in the production of a standardized cephalin preparation was to produce a crude phospholipid suspension which showed good sensitivity to the intrinsic clotting defect induced by oral anticoagulants. By modification of and experimentation with the Hjort method (1955) for the production of cephalin from human brain, more sensitive preparations were made. Initially our preparations were of the order of sensitivity of our human brain A and varied considerably between batches.
The first problem therefore was to develop the maximum sensitivity to the intrinsic clotting defect. Many modifications of the human brain cephalin preparation were compared using results of stabilized patients on oral anticoagulant therapy. The aim was to develop the maximum sensitivity combined with reasonable prolongation of the normal value. It was also considered preferable to activate the plasma, as the unactivated cephalin method, although a good test, is more subject to variability in technique of blood collection and storage in vitro thantheactivated method. A 10-minute kaolin activation was chosen. The kaolin activation time with the different techniques varies from a minute or so up to 20 minutes. Even 10 minutes does not give absolutely complete activation and Hardisty and Hutton (1965) recommended 20 minutes. A 20-minute incubation time makes the test very lengthy, and, as activation is almost complete at 10 minutes, this time was preferred.
A large batch of human brain cephalin B has been prepared in lyophilized form. It is stored at -70°C, and degradation studies carried out at 50°C, 370C, room temperature, and -200C indicate that it should be stable at low temperature for a long time. Subsequent working batches of cephalin reagent have been made to conform with the standardized preparation, in a similar way to the method of preparation of the British Comparative Thromboplastin. Working batches of cephalin reagent have been offered to hospitals in the national system for anticoagulant control for clinical assessment. Over 200 hospitals have requested and received supplies of working cephalin reagent. If the preparation and cephalin time method recommended prove acceptable this could provide a basis for a national system for testing and reporting.
